Delcath Systems (NASDAQ:DCTH) and Pulse Biosciences (NASDAQ:PLSE) Head-To-Head Contrast

Pulse Biosciences (NASDAQ:PLSE) and Delcath Systems (NASDAQ:DCTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Pulse Biosciences and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Delcath Systems	0.62%	0.51%	0.46%

Risk and Volatility

Pulse Biosciences has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Earnings and Valuation

This table compares Pulse Biosciences and Delcath Systems”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	5,774.09	-$72.78 million	($1.10)	-26.55
Delcath Systems	$85.23 million	5.35	$2.70 million	$0.01	1,320.00

Delcath Systems has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Pulse Biosciences and Delcath Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	3	0	2.50
Delcath Systems	2	0	5	0	2.43

Pulse Biosciences presently has a consensus price target of $30.67, suggesting a potential upside of 5.02%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 70.45%. Given Delcath Systems’ higher probable upside, analysts clearly believe Delcath Systems is more favorable than Pulse Biosciences.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Delcath Systems beats Pulse Biosciences on 9 of the 14 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.